Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- ASKA Aims at Sales of ¥50 Bil. in FY2012
May 3, 2010
- PMDA Must Accelerate Hiring of Reviewers: Mr Osa
May 3, 2010
- Shionogi, Eli Lilly Japan to Comarket Cymbalta
May 3, 2010
- PMDA, NIBIO to Be Targeted in 2nd Round of Screening
May 3, 2010
- Novartis Confident of Being Able to Differentiate Equa from Other DPP-4 Inhibitors
May 3, 2010
- PMDA's Reform Proposal Found Insufficient by Majority of Screeners: Internal Screening
May 3, 2010
- NEW PRODUCT
May 3, 2010
- MTPC Voluntarily Refrains from Promoting 7 Products Exempted from Sanction
May 3, 2010
- Merck Serono Aims to Become Leading Company in Oncology: Dr Wein
May 3, 2010
- Chuikyo Members Call For Penalties for Fraudulent Practice
May 3, 2010
- JPMA Removes All MTPC Representatives from Executive Positions
May 3, 2010
- Japan Should Accept More Overseas Clinical Data: Mr Dunoyer
May 3, 2010
- Astellas Launches Prograf in India
May 3, 2010
- Positive Efficacy Data Obtained for MDV3100 in PI, PII: Astellas, Medivation
May 3, 2010
- Eisai Licenses Cinitapride from Almirall in China
May 3, 2010
- Lawmakers to Include Lifting of Ban on Online Sales of Drugs in DPJ Manifesto
May 3, 2010
- Sanofi-aventis Licenses New Diabetes Treatment from CureDM Sign
May 3, 2010
- No Call for Lifting of Ban on Kongo Shinryo from DPJ Lawmakers
May 3, 2010
- AnGes to Discuss Licensing of ILTS with MEDRx
April 26, 2010
- BI Successfully Completes Tender Offer on SSP
April 26, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…